Education:
Postdoctoral fellowship, Molecular Oncology, Van Andel Research Institute, Michigan, US Ph.D., Oncology, Fudan University Shanghai Medical College, Shanghai, China M.D., Preventive Medicine, Shanghai Medical University, Shanghai, China
Research/Teaching Interests:
Brain tumor invasion, targeted thereapy for cancer and immunotherapy in cancer.
The success of molecular targeted therapy in cancer depends on knowledge of essential pathways that contribute to oncogenesis and the molecular targets that control pathway activity. My lab studies molecular oncology and targeted therapy with a focus on developing therapeutic strategies for targeting MET receptor tyrosine kinases (RTK) in glioblastoma and hepatocellular carcinoma. Previous work from this lab has elucidated molecular mechanisms of MET-targeting small molecule inhibitors, neutralizing antibodies as anti-cancer therapeutics. Patient-derived xenograft models and transgenic mouse models have been established for evaluating the therapeutic efficacy. Our recent research interests have been to develop MET-targeting chimeric antigen receptor (MET-CAR) T cells for treating MET-positive tumors and to understand the molecular mechanisms of therapeutic responses.